Litigation Details for Vireo Systems, Inc. v. GNC Holdings, Inc. (D. Neb. 2018)
✉ Email this page to a colleague
Vireo Systems, Inc. v. GNC Holdings, Inc. (D. Neb. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-04-09 |
| Court | District Court, D. Nebraska | Date Terminated | 2019-02-14 |
| Cause | 15:1126 Patent Infringement | Assigned To | Robert F. Rossiter Jr. |
| Jury Demand | Plaintiff | Referred To | Cheryl R. Zwart |
| Parties | NE ENTERPRISES INC. | ||
| Patents | 8,962,685; 9,486,424 | ||
| Attorneys | Jason S. Jackson | ||
| Firms | The Webb Law Firm | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Vireo Systems, Inc. v. GNC Holdings, Inc.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Vireo Systems, Inc. v. GNC Holdings, Inc. (D. Neb. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-10-17 | 32 | asserted patents: U.S. 8,354,450 (“the ‘450 Patent”); U.S. 8,962,685 (“the ‘685 Patent”); and U.S…over two prior patents, U.S. Patent No. 8,026,385 (“the ‘385 Patent”) and U.S. Patent No. 7,608,641…obviate a double patenting rejection over two prior patents, the ‘641 Patent and the ‘385 Patent. SOF, ¶ 12… ‘424 Patent is a continuation of the ‘685 Patent, which is a divisional of the ‘450 Patent, which… records further indicate that a patent to which the asserted patents claim priority thus the inventions | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
